La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Hologic Gestione

Gestione criteri di controllo 4/4

Hologic's Il CEO è Steve MacMillan, nominato in Dec2013, e ha un mandato di 10.67 anni. la retribuzione annua totale è $ 15.56M, composta da 7.6% di stipendio e 92.4% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.99% delle azioni della società, per un valore di $ 187.76M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 3.5 anni e 7.7 anni.

Informazioni chiave

Steve MacMillan

Amministratore delegato

US$15.6m

Compenso totale

Percentuale dello stipendio del CEO	7.6%
Mandato del CEO	10.8yrs
Proprietà del CEO	1.0%
Durata media del management	3.6yrs
Durata media del Consiglio di amministrazione	7.8yrs

Aggiornamenti recenti sulla gestione

Recent updates

These 4 Measures Indicate That Hologic (NASDAQ:HOLX) Is Using Debt Reasonably Well

Jun 20

Returns At Hologic (NASDAQ:HOLX) Appear To Be Weighed Down

May 22

Hologic: Women's Health Play Looks Healthier Itself

May 13

Getting In Cheap On Hologic, Inc. (NASDAQ:HOLX) Might Be Difficult

Apr 19

Calculating The Intrinsic Value Of Hologic, Inc. (NASDAQ:HOLX)

Apr 05

Hologic (NASDAQ:HOLX) Has A Pretty Healthy Balance Sheet

Mar 20

Why Hologic, Inc. (NASDAQ:HOLX) Could Be Worth Watching

Feb 22

Hologic: Prospects For Growth As Headwinds Disappear

Feb 11

We Think You Can Look Beyond Hologic's (NASDAQ:HOLX) Lackluster Earnings

Feb 09

Hologic, Inc. Just Beat EPS By 32%: Here's What Analysts Think Will Happen Next

Feb 06

We Like These Underlying Return On Capital Trends At Hologic (NASDAQ:HOLX)

Jan 29

The Price Is Right For Hologic, Inc. (NASDAQ:HOLX)

Dec 30

Are Investors Undervaluing Hologic, Inc. (NASDAQ:HOLX) By 25%?

Dec 11

We Think Hologic (NASDAQ:HOLX) Can Stay On Top Of Its Debt

Nov 08

Should You Think About Buying Hologic, Inc. (NASDAQ:HOLX) Now?

Oct 25

Slowing Rates Of Return At Hologic (NASDAQ:HOLX) Leave Little Room For Excitement

Sep 28

Hologic, Inc.'s (NASDAQ:HOLX) Intrinsic Value Is Potentially 35% Above Its Share Price

Aug 29

We Think Hologic (NASDAQ:HOLX) Can Stay On Top Of Its Debt

Jul 31

Why Hologic, Inc. (NASDAQ:HOLX) Could Be Worth Watching

Jul 18

Return Trends At Hologic (NASDAQ:HOLX) Aren't Appealing

Jun 21

Calculating The Fair Value Of Hologic, Inc. (NASDAQ:HOLX)

May 22

We Think Hologic (NASDAQ:HOLX) Can Stay On Top Of Its Debt

Apr 25

What Does Hologic, Inc.'s (NASDAQ:HOLX) Share Price Indicate?

Apr 10

Hologic's (NASDAQ:HOLX) Returns On Capital Are Heading Higher

Mar 13

Calculating The Fair Value Of Hologic, Inc. (NASDAQ:HOLX)

Feb 14

Hologic (NASDAQ:HOLX) Seems To Use Debt Quite Sensibly

Jan 18

Is Now The Time To Look At Buying Hologic, Inc. (NASDAQ:HOLX)?

Jan 03

Shareholders Would Enjoy A Repeat Of Hologic's (NASDAQ:HOLX) Recent Growth In Returns

Dec 02

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Steve MacMillan rispetto agli utili di Hologic?
Data	Compenso totale	Stipendio	Guadagni aziendali
Jun 29 2024	n/a	n/a	US$702m
Mar 30 2024	n/a	n/a	US$467m
Dec 30 2023	n/a	n/a	US$515m
Sep 30 2023	US$16m	US$1m	US$456m
Jul 01 2023	n/a	n/a	US$484m
Apr 01 2023	n/a	n/a	US$753m
Dec 31 2022	n/a	n/a	US$990m
Sep 24 2022	US$14m	US$1m	US$1b
Jun 25 2022	n/a	n/a	US$2b
Mar 26 2022	n/a	n/a	US$2b
Dec 25 2021	n/a	n/a	US$2b
Sep 25 2021	US$15m	US$1m	US$2b
Jun 26 2021	n/a	n/a	US$2b
Mar 27 2021	n/a	n/a	US$2b
Dec 26 2020	n/a	n/a	US$1b
Sep 26 2020	US$14m	US$1m	US$1b
Jun 27 2020	n/a	n/a	US$497m
Mar 28 2020	n/a	n/a	US$453m
Dec 28 2019	n/a	n/a	US$84m
Sep 28 2019	US$12m	US$1m	-US$204m
Jun 29 2019	n/a	n/a	-US$30m
Mar 30 2019	n/a	n/a	-US$11m
Dec 29 2018	n/a	n/a	-US$419m
Sep 29 2018	US$42m	US$1m	-US$111m
Jun 30 2018	n/a	n/a	-US$79m
Mar 31 2018	n/a	n/a	-US$132m
Dec 30 2017	n/a	n/a	US$1b
Sep 30 2017	US$11m	US$1m	US$756m

Compensazione vs Mercato: La retribuzione totale di Steve ($USD 15.56M ) è circa la media per le aziende di dimensioni simili nel mercato US ($USD 13.21M ).

Compensazione vs guadagni: La retribuzione di Steve è stata coerente con le performance aziendali dell'ultimo anno.

AMMINISTRATORE DELEGATO

Steve MacMillan (60 yo)

10.8yrs

Mandato

US$15,555,032

Compensazione

Mr. Stephen P. MacMillan, also known as Steve, serves as an Independent Chairman of the Board at Illumina, Inc. from June 02, 2023. He has been the Chairman of the Board at Hologic Inc. since June 17, 2015...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Stephen MacMillan	Chairman	10.8yrs	US$15.56m	0.99% $ 186.2m
Karleen Oberton	Chief Financial Officer	6.1yrs	US$3.93m	0.036% $ 6.8m
Essex Mitchell	Chief Operating Officer	less than a year	US$2.17m	0.00018% $ 33.8k
John Griffin	General Counsel	9.6yrs	US$3.34m	0.046% $ 8.6m
Jan Verstreken	Group President of International	no data	US$3.52m	0.031% $ 5.9m
Paul Malenchini	Chief Information Officer	3.2yrs	Nessun dato	Nessun dato
Ryan Simon	Vice President of Investor Relations	no data	Nessun dato	Nessun dato
Diana De Walt	Senior Vice President of Global Human Resources	less than a year	Nessun dato	Nessun dato
Monica Berthelot	VP & Chief of Staff	10.7yrs	Nessun dato	Nessun dato
Erik Anderson	Division President of Breast & Skeletal Health Solutions	4.1yrs	Nessun dato	0.0071% $ 1.3m
Jennifer Schneiders	President of Diagnostics Solutions	1.4yrs	Nessun dato	0.0027% $ 512.5k
Scott Christensen	Senior Vice President of Global Supply Chain	less than a year	Nessun dato	Nessun dato

3.6yrs

Durata media

56yo

Età media

Gestione esperta: Il team dirigenziale di HOLX è considerato esperto (durata media dell'incarico 3.5 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Stephen MacMillan	Chairman	10.8yrs	US$15.56m	0.99% $ 186.2m
Scott Garrett	Independent Director	11.3yrs	US$339.96k	0.018% $ 3.4m
Sally Crawford	Independent Director	16.9yrs	US$374.96k	0.057% $ 10.6m
Stacey Stewart	Independent Director	1.7yrs	US$338.44k	0.000070% $ 13.1k
Ludwig Hantson	Independent Director	5.8yrs	US$319.96k	0.0025% $ 471.2k
Charles Dockendorff	Independent Director	7.3yrs	US$344.96k	0.0066% $ 1.2m
Christiana Stamoulis	Independent Director	12.8yrs	US$319.96k	0.019% $ 3.5m
Amy Wendell	Lead Independent Director	7.8yrs	US$319.96k	0.0076% $ 1.4m
Nanaz Mohtashami	Independent Director	less than a year	US$128.96k	0.00032% $ 60.1k

7.8yrs

Durata media

61yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di HOLX sono considerati esperti (durata media dell'incarico 7.7 anni).

Hologic Gestione

Gestione criteri di controllo 4/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Chief Financial Officer notifies of intention to sell stock

Chairman notifies of intention to sell stock

Independent Director notifies of intention to sell stock

Hologic, Inc., Annual General Meeting, Mar 07, 2024

Namal Nawana Announces Not to Stand for Re-Election to the Board of Hologic, Inc

Independent Director notifies of intention to sell stock

Recent updates

Hologic (NASDAQ:HOLX) Has More To Do To Multiply In Value Going Forward

Hologic, Inc. (NasdaqGS:HOLX) announces an Equity Buyback for $1,500 million worth of its shares.

Hologic, Inc. (NASDAQ:HOLX) Not Flying Under The Radar

Chief Financial Officer notifies of intention to sell stock

Hologic Has A Lot Of Fine Qualities, But A Discount Valuation Isn't Among Them

Chairman notifies of intention to sell stock

Hologic, Inc. Provides Earnings Guidance for the Fourth Quarter of 2024

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Hologic, Inc. (NasdaqGS:HOLX) completed the acquisition of Endomagnetics Ltd. for approximately $310 million.

Is There Now An Opportunity In Hologic, Inc. (NASDAQ:HOLX)?

Hologic, Inc. to Report Q3, 2024 Results on Jul 29, 2024

Now 19% undervalued after recent price drop

Now 20% undervalued after recent price drop

These 4 Measures Indicate That Hologic (NASDAQ:HOLX) Is Using Debt Reasonably Well

Now 20% undervalued after recent price drop

Now 20% undervalued after recent price drop

Returns At Hologic (NASDAQ:HOLX) Appear To Be Weighed Down

Hologic: Women's Health Play Looks Healthier Itself

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Hologic, Inc. Reports Impairment of Intangible Assets for the Second Quarter Ended March 30, 2024

Hologic, Inc. (NasdaqGS:HOLX) signed a definitive agreement to acquire Endomagnetics Ltd. for approximately $310 million.

Getting In Cheap On Hologic, Inc. (NASDAQ:HOLX) Might Be Difficult

Now 20% undervalued

Calculating The Intrinsic Value Of Hologic, Inc. (NASDAQ:HOLX)

Hologic, Inc. to Report Q2, 2024 Results on May 02, 2024

Hologic (NASDAQ:HOLX) Has A Pretty Healthy Balance Sheet

Independent Director notifies of intention to sell stock

Now 20% undervalued

Hologic, Inc. and Biotheranostics, Inc. Announces Newly Published Study Results Reveal That Use of the Breast Cancer Index®? Test

Now 20% undervalued

Why Hologic, Inc. (NASDAQ:HOLX) Could Be Worth Watching

Hologic: Prospects For Growth As Headwinds Disappear

We Think You Can Look Beyond Hologic's (NASDAQ:HOLX) Lackluster Earnings

Hologic, Inc. Just Beat EPS By 32%: Here's What Analysts Think Will Happen Next

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Hologic, Inc. Revises Earnings Guidance for the Fiscal Year 2024

We Like These Underlying Return On Capital Trends At Hologic (NASDAQ:HOLX)

Now 21% undervalued

Hologic, Inc., Annual General Meeting, Mar 07, 2024

Namal Nawana Announces Not to Stand for Re-Election to the Board of Hologic, Inc

Now 21% undervalued

Hologic, Inc. Provides Revenue Guidance for the First Quarter of 2024

Hologic, Inc. to Report Q1, 2024 Results on Feb 01, 2024

Independent Director notifies of intention to sell stock

The Price Is Right For Hologic, Inc. (NASDAQ:HOLX)

Are Investors Undervaluing Hologic, Inc. (NASDAQ:HOLX) By 25%?

Hologic, Inc. Promotes Essex D. Mitchell to Chief Operating Officer

Chairman exercised options and sold US$2.1m worth of stock

Hologic, Inc. Provides Earnings Guidance for the First Quarter and Full-Year Fiscal 2024

Full year 2023 earnings: EPS misses analyst expectations

Hologic, Inc. (NasdaqGS:HOLX) announces an Equity Buyback for $500 million worth of its shares.

We Think Hologic (NASDAQ:HOLX) Can Stay On Top Of Its Debt

Should You Think About Buying Hologic, Inc. (NASDAQ:HOLX) Now?

Hologic, Inc. to Report Q4, 2023 Results on Nov 09, 2023

Slowing Rates Of Return At Hologic (NASDAQ:HOLX) Leave Little Room For Excitement

Nanaz Mohtashami Elected to Hologic, Inc.'S Board of Directors

Hologic, Inc.'s (NASDAQ:HOLX) Intrinsic Value Is Potentially 35% Above Its Share Price

Consensus EPS estimates fall by 22%

Hologic, Inc. Reports Impairment Charges for the Third Quarter Ended July 1, 2023

New minor risk - Earnings quality

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Hologic, Inc. Revises Earnings Guidance for the Fiscal Year 2023

We Think Hologic (NASDAQ:HOLX) Can Stay On Top Of Its Debt

Why Hologic, Inc. (NASDAQ:HOLX) Could Be Worth Watching

Hologic, Inc. to Report Q3, 2023 Results on Jul 31, 2023

Return Trends At Hologic (NASDAQ:HOLX) Aren't Appealing

Calculating The Fair Value Of Hologic, Inc. (NASDAQ:HOLX)

Hologic, Inc. Announces FDA Clearance of Panther Fusion SARS-CoV-2/Flu A/B/RSV Assay

Insider recently sold US$200k worth of stock